Non-alcoholic fatty liver disease epidemiology and demographics: Difference between revisions
Aditya Ganti (talk | contribs) |
Aditya Ganti (talk | contribs) |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The estimated annual incidence of non alcoholic liver disease with steatosis in the United States is approximately 9,255 per 100,000 individuals. The prevalence of non-alcoholic liver disease in the United States is estimated to be 10,000 to 24,000 cases per 100,000 individuals annually. Non-alcoholic fatty liver disease may occur at any age, but is diagnosed most commonly in patients aged 50 to 60 years. [[Hepatic]] [[steatosis]] is more prevalent in the hispanics. | |||
==Epidemiology == | ==Epidemiology == | ||
Revision as of 21:19, 22 December 2017
|
Non-Alcoholic Fatty Liver Disease Microchapters |
|
Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case studies |
|
Non-alcoholic fatty liver disease epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Non-alcoholic fatty liver disease epidemiology and demographics |
|
FDA on Non-alcoholic fatty liver disease epidemiology and demographics |
|
CDC on Non-alcoholic fatty liver disease epidemiology and demographics |
|
Non-alcoholic fatty liver disease epidemiology and demographics in the news |
|
Blogs on Non-alcoholic fatty liver disease epidemiology and demographics |
|
Directions to Hospitals Treating Non-alcoholic fatty liver disease |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
Overview
The estimated annual incidence of non alcoholic liver disease with steatosis in the United States is approximately 9,255 per 100,000 individuals. The prevalence of non-alcoholic liver disease in the United States is estimated to be 10,000 to 24,000 cases per 100,000 individuals annually. Non-alcoholic fatty liver disease may occur at any age, but is diagnosed most commonly in patients aged 50 to 60 years. Hepatic steatosis is more prevalent in the hispanics.
Epidemiology
Incidence
- The estimated annual incidence of non alcoholic liver disease with steatosis in the United States is approximately 9,255 per 100,000 individuals.
- The estimated annual incidence of non alcoholic liver disease with steatohepatitis in the United States is approximately 265 per 100,000 individuals .
- About 1/3 of america population is expected to have non alcoholic fatty liver disease.[1][2][3][4][5]
Prevalance
- The prevalence of non-alcoholic liver disease in the United States is estimated to be 10,000 to 24,000 cases per 100,000 individuals annually.
- In obese children the prevalence of non-alcoholic liver disease is estimated to be 20,000 to 50,000 cases per 100,000 individuals annually.[6]
- Prevalence of non-alcoholic fatty liver disease increases nearly five fold in obese individuals.
Demographics
Age
- Non-alcoholic fatty liver disease may occur at any age, but is diagnosed most commonly in patients aged 50 to 60 years.
Gender
- Men are more commonly affected by non-alcoholic liver disease than women.
- Among women it is more common in post-menopausal women than pre-menopausal.
Race
- Hepatic steatosis is more prevalent in the hispanics (45%) race and followed by caucasians (42% of men, 24% of women) and african-american (24%)
References
- ↑ Bellentani S, Scaglioni F, Marino M, Bedogni G (2010). "Epidemiology of non-alcoholic fatty liver disease". Dig Dis. 28 (1): 155–61. doi:10.1159/000282080. PMID 20460905.
- ↑ Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M (2014). "Non alcoholic fatty liver: epidemiology and natural history". Rev Recent Clin Trials. 9 (3): 126–33. PMID 25514916.
- ↑ Le MH, Devaki P, Ha NB, Jun DW, Te HS, Cheung RC; et al. (2017). "Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States". PLoS One. 12 (3): e0173499. doi:10.1371/journal.pone.0173499. PMC 5367688. PMID 28346543.
- ↑ Fan JG, Farrell GC (2009). "Epidemiology of non-alcoholic fatty liver disease in China". J Hepatol. 50 (1): 204–10. doi:10.1016/j.jhep.2008.10.010. PMID 19014878.
- ↑ Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.
- ↑ Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.